In addition to the classic catabolic effects, it is now widely accepted that parathyroid hormone (PTH) exerts anabolic effects on bone, when administered intermittently. As a result of the regenerative characteristic, Teriparatide (Forsteo® Europe, Forteo® U.S.A., Eli Lilly) which is a recombinant PTH (1-34), was recently approved for treatment of osteoporosis in the USA and the Europe. The dual actions of PTH are mediated primarily through PTH receptor 1 (PTH1R), which is a class II G protein-coupled receptor. PTH1R can activate diverse signaling pathways, including cAMP/PKA and PLC/PKC pathways (Vilardaga et al., 2011). Periodontitis is an inflammatory disease, which manifests clinically as loss of supporting periodontal tissues. Accumula...